Assessing the efficacy of TNF-alpha inhibitors in preventing emergency and emergent colectomies.
TNF‐∝ inhibitors
emergency colectomy
inflammatory bowel disease
infliximab
ulcerative colitis
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
16
04
2019
accepted:
08
06
2019
entrez:
14
4
2020
pubmed:
14
4
2020
medline:
14
4
2020
Statut:
epublish
Résumé
Severe ulcerative colitis (UC) is potentially life threatening and is associated with significant morbidity. TNF-∝ inhibitors (Infliximab) were introduced in Australia for the management of medically resistant, acute, severe flares of UC in 2008. The aim of this study is to assess the efficacy of Infliximab in preventing emergent and emergency colectomies for patients with moderate to severe UC by comparing colectomy rates before and after its introduction at our institution. This was a retrospective cohort study of all patients who were admitted to the Royal Perth Hospital with a flare of UC between 2002 and 2017. Patients were divided into two cohorts: those admitted prior to the introduction of Infliximab (pre-2008) and those admitted after. We compared data between these two groups, including age, gender, length of admission, use of Infliximab, colectomy, and complications of surgery. We defined emergency surgery as requiring surgery during the index admission and emergent surgery as an operation within 54 weeks. A total of 313 UC cases from 2002 to 2017 were analyzed. There was a decrease in emergency and emergent colectomies from 19.4 to 8% in the post-2008 cohort ( Overall, the need for emergency and emergent operations has drastically reduced at our institution with the introduction of Infliximab. This study has confirmed the efficacy of Infliximab in reducing colectomy rates at our institution.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Severe ulcerative colitis (UC) is potentially life threatening and is associated with significant morbidity. TNF-∝ inhibitors (Infliximab) were introduced in Australia for the management of medically resistant, acute, severe flares of UC in 2008. The aim of this study is to assess the efficacy of Infliximab in preventing emergent and emergency colectomies for patients with moderate to severe UC by comparing colectomy rates before and after its introduction at our institution.
METHODS
METHODS
This was a retrospective cohort study of all patients who were admitted to the Royal Perth Hospital with a flare of UC between 2002 and 2017. Patients were divided into two cohorts: those admitted prior to the introduction of Infliximab (pre-2008) and those admitted after. We compared data between these two groups, including age, gender, length of admission, use of Infliximab, colectomy, and complications of surgery. We defined emergency surgery as requiring surgery during the index admission and emergent surgery as an operation within 54 weeks.
RESULTS
RESULTS
A total of 313 UC cases from 2002 to 2017 were analyzed. There was a decrease in emergency and emergent colectomies from 19.4 to 8% in the post-2008 cohort (
CONCLUSION
CONCLUSIONS
Overall, the need for emergency and emergent operations has drastically reduced at our institution with the introduction of Infliximab. This study has confirmed the efficacy of Infliximab in reducing colectomy rates at our institution.
Identifiants
pubmed: 32280756
doi: 10.1002/jgh3.12229
pii: JGH312229
pmc: PMC7144788
doi:
Types de publication
Journal Article
Langues
eng
Pagination
140-144Informations de copyright
© 2019 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Patient Saf Surg. 2014 Jul 26;8:31
pubmed: 25075222
Dig Liver Dis. 2008 Oct;40(10):821-6
pubmed: 18472316
Am J Gastroenterol. 2012 Dec;107(12):1879-87
pubmed: 23165448
J Dig Dis. 2015 Oct;16(10):558-67
pubmed: 26315728
Nat Rev Gastroenterol Hepatol. 2016 Jan;13(1):13-27
pubmed: 26627550
Clin Gastroenterol Hepatol. 2011 Nov;9(11):972-80
pubmed: 21806954
N Engl J Med. 2005 Dec 8;353(23):2462-76
pubmed: 16339095
Br Med J. 1955 Oct 29;2(4947):1041-8
pubmed: 13260656
Blood. 2006 Jul 1;108(1):253-61
pubmed: 16537805
Am J Surg. 2013 Mar;205(3):333-7; discussion 337-8
pubmed: 23369311
Aliment Pharmacol Ther. 2014 Sep;40(6):629-38
pubmed: 25039715
Inflamm Bowel Dis. 2010 Sep;16(9):1550-6
pubmed: 20803698
Gastroenterology. 2009 Oct;137(4):1250-60; quiz 1520
pubmed: 19596014